⌕
Avalo Therapeutics · AVTX · Nasdaq
Tenet 55 · Mixed
Compare
$6.76+0.15%At closeTenet 55 · Mixed
$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Avalo Therapeutics (AVTX) Earnings Forecast

Analysts expect Avalo Therapeutics (AVTX) to lose $2.42 a share in FY26, the average of 8 estimates as of Nov 21, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice
FY26 consensus EPS
$−2.42
8 analysts
FY27 consensus EPS
$−2.36
9 analysts · low $−2.89, high $−1.50
EPS revisions, 30 days
+17.1%
$−2.92 to $−2.42
Disagreement, FY26
$0.49
wide, $−2.71 to $−2.22

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 21, 2026 · we check it nightly

Analysts expect Avalo Therapeutics to lose $1.71 a share in FY30; 2 analysts publish an estimate for FY30.

Forward P/E · FY26E
n/m
a multiple of a loss is not meaningful
Coverage · FY26
8 · 12
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $−2.42, a loss that narrowed 15.6% in 90 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 90 days. One step per nightly change.

−7.5%+7.2%+21.8%FY27 +17.9%FY26 +15.6%Aug 23Nov 21
EPS30 days90 daysshown aboveSince Jul 10
FY268 analysts▲ +17.1%$−2.92 to $−2.42▲ +15.6%$−2.86 to $−2.42▲ +19.1%$−2.99 to $−2.42
FY279 analysts▲ +20.7%$−2.98 to $−2.36▲ +17.9%$−2.88 to $−2.36▲ +21.1%$−2.99 to $−2.36
Dec '267 analysts▲ +17.3%$−0.55 to $−0.45▲ +13.0%$−0.52 to $−0.45▲ +10.1%$−0.50 to $−0.45
Mar '273 analysts6 of 30 days0.0% so far6 of 90 days0.0% so far◆ 0.0%$−0.51 to $−0.51

Contributors at both ends of the window: FY26 10 and 8. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price at last close · consensus as of Nov 21, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from the first positive year on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY26
$−0.0B
8 analysts · low $−0.0B, high $−0.0B · thin coverage
Multiple · five-year average P/E
10.7×
Average of the fiscal-year P/Es, FY17 to FY17.
×
Receipt · AVTX · FY26Nov 21, 2026
Implied, a share
Waiting

We hold no net cash and no diluted share count for this company, so an EBITDA multiple cannot be bridged to a price a share here. The sum stops rather than guessing the bridge.

Drag the multipleShaded: where Avalo Therapeutics' P/E sat at each fiscal year end, FY17 to FY17. Each dot is one year.
6×8×10×12×14×16×
5-yr avg 10.7×10-yr median 10.7×

Each point on the line is a multiple, and the flag is the price it implies for FY26. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY30, estimates run from $−1.71 to $−1.71 around an average of $−1.71, drawn by 2 analysts.

FY26E8 analysts
$−2.71 to $−2.22 · $0.49 wide
FY27E9 analysts
$−2.89 to $−1.50 · $1.38 wide
FY28E6 analysts
$−3.04 to $−1.78 · $1.25 wide
FY29E3 analysts
$−2.60 · only 3 estimates
FY30E2 analysts
$−1.71 · only 2 estimates

The dashed line is FY25 filed $−5.84, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Avalo Therapeutics to lose $0.45 a share in the December quarter, the average of 7 estimates. We hold no expected date for the next report. Last quarter, which ended in September, Avalo Therapeutics lost $0.34 a share. Analysts had expected a loss of $0.59, so the loss came in 42.2% smaller.

0
$−1.02
$−0.45high $−0.35
low $−0.52
Dec 2025 quarterfiled · GAAPDec 2026 quarterconsensus · Street basis · 7 analysts
Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$0.0K
0 analysts, 0.0 to 0.0 in $K · 59.0 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the March quarter, analysts expect a loss of $0.51 a share.

Does Avalo Therapeutics usually beat or miss?

So far we have checked 1 quarter: the one that ended in September 2026, when Avalo Therapeutics lost $0.34 a share against the a loss of $0.59 analysts expected, 42.2% smaller. We add a quarter to this record each time Avalo Therapeutics reports.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Before our record
Sep '25
Dec '25
Mar '26
Our record, one quarter per report
Jun '26left out
+42.2%
Sep '26reaction
−6.2%
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Checked so far
1 quarter
one more every report
Beat expectations
1 of 1
full details on the Earnings tab
Share price reaction
−6.2%
one session, timed to the September 2026 release
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Avalo Therapeutics on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 0.0% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

8 analysts publish an EPS estimate for FY26 and 12 publish revenue. Coverage thins with distance: 2 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
128
FY26E
129
FY27E
66
FY28E
43
FY29E
32
FY30E
The FY26 panel held 10 analysts when our record of it began on Jul 10, 2026 and holds 8 tonight.

The full consensus, year by year

Consensus as of Nov 21, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.00.10.1historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 12 revenue estimates for FY26, 3 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−1,126.69−542.8740.96historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 8 EPS estimates for FY26, 2 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.0—−5.84————as filed—
FY26E0.00.0 to 0.0▲1594.9%a−2.42−2.71 to −2.22n/ca−0.0−0.00.0112 · 8n/m
FY27E0.00.0 to 0.0▲0.0%−2.36−2.89 to −1.50—−0.0−0.00.0112 · 9n/m
FY28E0.00.0 to 0.0n/cb−2.34−3.04 to −1.78—−0.0−0.00.016 · 6n/m
FY29E0.00.0 to 0.0▲63570.4%−2.60−2.60 to −2.60n/cb−0.0−0.00.014 · 3n/m
FY30E0.10.1 to 0.1▲1056.0%−1.71−1.71 to −1.71—−0.0−0.00.013 · 2n/m

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 8 EPS estimates for FY26, 12 for revenue. Not investment advice.

What do analysts expect Avalo Therapeutics to earn in FY26?

Analysts expect Avalo Therapeutics to lose $2.42 a share in FY26, the average of 8 estimates as of Nov 21, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.